Switching treatments in clinically stable relapsing remitting multiple sclerosis patients planning for pregnancy.

found that ARR was reduced by 23% after switching from IFN to GA – switched due to toxicity-, and this reduction did not reach statistical significance. 36 A case report of a 25-year-old woman with relapsing remitting MS who was initially using IFN-ß-1a for nine months and switched to GA due to the flu like side effect, showed clinical stability on GA for five years while radiological activity was not reported. 37 Lastly, a 39-year-old woman with relapsing remitting disease for four years, switched from IFN-ß-1a to GA due to side effects.

also in 111,027 other papers